VA-HILTON-HOTELS
15.7.2015 20:01:13 CEST | Business Wire | Pressemeddelelse
Hilton Hotels & Resorts , the flagship brand of Hilton Worldwide (NYSE: HLT), announced today the opening of the 355-room Hilton Aruba Caribbean Resort & Casino , a 15-acre beachfront oasis in Palm Beach, Aruba. With a privileged location on picturesque white sand beaches, this upscale resort in Aruba welcomes travelers to one of the Caribbean’s most desired destinations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150715006334/en/
“Aruba is the quintessential Caribbean island with its strong European influence, long stretches of white beach and eclectic culinary scene,” said Rob Palleschi, global head, full service brands, Hilton Worldwide. “As one of the most revisited destinations in the region, this opening marks an important milestone as we continue to expand our global presence and deliver on our commitment to providing diverse experiences for our guests.”
Located on the largest beachfront stretch of Palm Beach and less than 10 miles from the capital city of Oranjestad, Hilton Aruba Caribbean Resort & Casino welcomes guests to a premier resort experience. Featuring glamorous architecture (the hotel was designed by Morris Lapidus, renowned architect of some of Miami's most famous hotels, as well as the The Condado Plaza Hilton and DoubleTree by Hilton Hotel Metropolitan – New York City), unmatched beaches, enchanting gardens, an expansive pool complex, kids club, watersports and dive center, world-class spa, on-site casino and culinary choices for the most discerning palate, this resort offers something for everyone.
“The opening of Hilton Aruba Caribbean Resort & Casino is celebrated with pride,” said Tom Potter, senior vice president, Caribbean, Mexico and Latin America, Hilton Worldwide. “This project is a magnificent addition to our Caribbean portfolio with its remarkable connection to the island’s past and exceptional team members who bring traditional Aruban hospitality to life. We are grateful for the opportunity to be a part of this hospitable community, and extend Hilton’s warm welcome to the island’s residents and visitors.”
Stay:
The upscale Hilton Aruba Caribbean Resort & Casino features 355 charming guest rooms, including executive floor rooms and suites, outfitted with comfortable and luxurious bedding, flat screen TVs, wireless Internet access, coffee maker and more. Rooms offer a tropical décor, views of the gardens, pools or sea, and spacious balconies for outdoor relaxation. Executive floor guests enjoy special access to an executive lounge, private concierge service and rooms featuring custom artwork.
Meet:
An ideal choice for weddings, corporate events, intimate parties and galas, the property provides nearly 40,000 square feet of indoor and outdoor event space for any occasion. Indoors, the hotel offers more than 15,000 square feet of flexible function space including eight meeting rooms with total capacity for more than 900 guests, five private intimate meeting rooms for smaller gatherings, a Grand Caribbean Ballroom accommodating more than 900 guests and two business centers. Outdoors, approximately 24,000 square feet of lush tropical landscape can accommodate up to 2,000 guests.
Eat:
Hilton Aruba Caribbean Resort & Casino offers a memorable dining experience with award-winning options offering everything from casual fare to fresh seafood. La Playa Torchlight Dinner offers a romantic beachfront exclusive dining experience with a personal server and four-course dinner, Gilligan’s Beach Bar & Grill is open for breakfast, lunch and dinner offering comfort food favorites in a friendly casual environment, Laguna Restaurant welcomes guests to indoor and outdoor dining featuring Caribbean fare and health-inspired cuisine, Mira Solo, meaning “look at the sun” in Papiamento, is the first and only martini and wine bar in Aruba and Sunset Grille is the resort’s award-winning signature restaurant serving international specialties including steak and seafood dishes.
Hilton Aruba Caribbean Resort & Casino participates in Hilton HHonors®, the award-winning guest-loyalty program for Hilton Worldwide’s twelve distinct hotel brands. Hilton HHonors Members always get our lowest price with our Best Price Guarantee, along with HHonors Points, free Wi-Fi, digital check-in and no booking fees only when they book directly through Hilton. To celebrate the opening, Hilton Aruba Caribbean Resort & Casino is offering 5,000 HHonors bonus points per stay through Oct. 31, 2015*.
Hilton Aruba Caribbean Resort & Casino is owned by Aruba Growth Fund (representing the main pension funds in Aruba, and their 10,000+ members) and its partners, and managed by Hilton Worldwide.
For more information and reservations, visit hilton.com or call 1-800-HILTONS.
*Minimum length of stay of three nights required. Other restrictions apply.
About Hilton Hotels & Resorts
Founded in 1919 as the flagship brand of Hilton Worldwide, Hilton Hotels & Resorts continues to build upon its legacy of innovation by developing products and services to meet the needs of savvy global travelers at more than 550 hotels across six continents. Hilton is the stylish, forward-thinking global leader in hospitality with Team Members shaping experiences in which every guest feels cared for, valued and respected. Access the latest news at news.hilton.com and begin your journey at www.hilton.com or www.hilton.com/offers for the latest hotel specials. Hilton Hotels & Resorts is one of Hilton Worldwide’s 12 brands.
About Hilton Worldwide
Hilton Worldwide (NYSE: HLT) is a leading global hospitality company, spanning the lodging sector from luxury and full-service hotels and resorts to extended-stay suites and focused-service hotels. For 95 years, Hilton Worldwide has been dedicated to continuing its tradition of providing exceptional guest experiences. The company's portfolio of twelve world-class global brands is comprised of more than 4,350 managed, franchised, owned and leased hotels and timeshare properties, with more than 720,000 rooms in 94 countries and territories, including Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonors®. Visit news.hiltonworldwide.com for more information and connect with Hilton Worldwide at facebook.com/hiltonworldwide , twitter.com/hiltonworldwide , youtube.com/hiltonworldwide , flickr.com/hiltonworldwide , and linkedin.com/company/hilton-worldwide .
About Aruba Growth Fund
The Aruba Growth Fund is a private equity fund established in 2012, and focuses on investments in well-established Aruban companies. The fund has a range of investors, including the largest pension funds in the country, as well as several respectable private companies and bank. Management of the fund is in the hands of BKM Management, an investment management company run by Rene Kan, Milton Berlinski and Justus Martens. Visit arubagrowthfund.com for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150715006334/en/
Contact:
Karla Visconti
Hilton Worldwide
+1 786 866 7240
karla.visconti@hilton.com
or
Michelle
Scully
For Hilton Hotels & Resorts
+1 312 240 2924
michelle.scully@edelman.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum